

# Preliminary Scientific Programme

## PLENARY LECTURES

- 1) Gene editing: powerful new tool for nephrology research and therapy  
**Toni Cathomen**, Freiburg, Germany
- 2) New paradigms of the kidney - Vascular-Bone axis in CKD  
**Klaus Olgaard**, Copenhagen, Denmark
- 3) From the RNA world to the clinic: RNAs as drugs and drug targets  
**Bruce Sullenger**, Durham, USA
- 4) Epidemiology of kidney disease  
**Marcello Tonelli**, Calgary, Canada

Liquid kidney biopsy  
- Yes! We are there  
**Harald Mischak**, Hannover, Germany  
- No, at least by now  
**Kerstin Amann**, Erlangen, Germany

The diagnosis of hematuria in the genetic era: a conundrum solved?  
*Speaker to be confirmed*

ANCA-associated vasculitis: should it be split into (at least) two diseases?  
**Benjamin Terrier**, Paris, France

New biomarkers in IgA nephropathy  
*Speaker to be confirmed*

## MINI LECTURES

Epigenetic changes induced by HIF  
*Speaker to be confirmed*

New ideas on the link between salt and hypertension  
**Friedrich C. Luft**, Berlin, Germany

Current place of vaptans in the treatment of hyponatremia  
**Goce Spasovski**, Skopje, F.Y.R. of Macedonia

Targeting non-coding RNA for the treatment of renal diseases  
*Speaker to be confirmed*

Economics of ADPKD: cost-effectiveness of medical treatment?  
**Jonathan G. Fox**, Glasgow, United Kingdom

Role of Wnt signaling in renal fibrosis  
*Speaker to be confirmed*

The new standardized classification of glomerulonephritis  
**Sanjeev Sethi**, Rochester, U.S.A.

Treatment of C3 nephropathy  
*Speaker to be confirmed*

Treatment of HUS  
**Giuseppe Remuzzi**, Bergamo, Italy

Treatment of HCV: challenges and opportunities  
**Michel Jadoul**, Brussels, Belgium

Changing face of HIV related kidney disorders  
**Alberto Ortiz**, Madrid, Spain

Frailty in CKD/ESRD  
**Dimitrios Goumenos**, Patras, Greece

How to increase serum Klotho concentration?  
**Makoto Kuro-o**, Shimotsuke, Japan

FGF23 as a predictor of cardiovascular outcomes in CKD  
**Martin De Borst**, Groningen, The Netherlands

Gut-microbiota in immune-mediated inflammatory diseases  
*Speaker to be confirmed*

Polypharmacy and compliance in CKD  
*Speaker to be confirmed*

Clinical trials in nephrology  
**Adeera Levin**, Vancouver, Canada

Inflammation as a driver of premature aging in CKD  
**Peter Stenvinkel**, Stockholm, Sweden

Atrial fibrillation in ESRD - what is the best approach to treatment  
**Adrian Covic**, Iasi, Romania

Milestones in hyperkalemia therapy or just an innovation  
**Ziad Massy**, Paris, France

Aldosterone inhibition in ESRD patients  
**Patrick Rossignol**, Vandoeuvre-Les-Nancy, France

Resistant hypertension in ESRD - is it just water that matters?  
*Speaker to be confirmed*

Implementation of new CKD-MBD guidelines  
**Markus Ketteler**, Coburg, Germany

Sacubitril/valsartan for treatment of chronic heart failure with reduced ejection fraction and CKD - something new on the horizon

**Richard Haynes**, Oxford, United Kingdom

Role of inflammation in anaemia of CKD patients

**Yalcin Solak**, Sakarya, Turkey

New clinical trials on organ transplantation

**Josep Cruzado**, Barcelona, Spain

Xenotransplantation - a realistic solution?

*Speaker to be confirmed*

Criteria to define transplantable kidneys

*Speaker to be confirmed*

How do we treat diabetic patients in stage 4-5 CKD

*Speaker to be confirmed*

Bariatric surgery and kidney functions

*Speaker to be confirmed*

The presence and the future of antihypertensive therapy

*Speaker to be confirmed*

The cirrhotic patient with AKI

*Speaker to be confirmed*

Staging AKI: from RIFLE to KDIGO to Delta-creatinine?

**Norbert H. Lameire**, Ghent, Belgium

CI-AKI: are the contrast agents really harmful?

**Jolanta Malyszko**, Bialystok, Poland

One mini lecture in collaboration with the International Association for the History of Nephrology (IAHN)



## SYMPOSIA

### SPECIAL AND JOINT SYMPOSIA

#### Late breaking clinical trials

**ERA-EDTA Registry**

ERA-EDTA Registry  Leading European Nephrology

**NDT Polar Views**

**ndt**

**American Society of Nephrology (ASN) Highlights**



**ERA-EDTA and Japanese Society of Nephrology (JSN)**



**ERA-EDTA and Chinese Society of Nephrology (CSN)**



**ERA-EDTA and European Society of Hypertension (ESH)**



**ERA-EDTA and European Society for Paediatric Nephrology (ESPN)**



#### Track 1

### FLUID & ELECTROLYTES, TUBULAR TRANSPORT, RENAL PHYSIOLOGY

#### Renal physiology - tubular transport

- Claudins in the distal nephron  
*Speaker to be confirmed*
- Tubular handling of calcium and magnesium: Insights from GWAS  
*Speaker to be confirmed*
- HNF1beta: roles in the distal nephron  
**Stanislas Guager**, Toulouse, France

#### Mitochondria: critical players in kidney disorders

- FAT1 and the control of mitochondrial function in the kidney  
*Speaker to be confirmed*
- Mitochondrial dysfunction in hereditary kidney disorders  
**Francesco Emma**, Rome, Italy
- Mitochondrial dysfunction in AKI  
**Ariela Benigni**, Bergamo, Italy

#### APOL1 impact in kidney disease

- Overview of the role of apolipoproteins  
**Arnold Von Eckardstein**, Zürich, Switzerland
- APOL1 and risk of multiple kidney disorders  
**Barry I. Freedman**, Winston-Salem, U.S.A.
- A mouse model of APOL1-associated kidney disease  
*Speaker to be confirmed*

# Preliminary Scientific Programme

## Track 2

### HEREDITARY DISORDERS, DEVELOPMENT, PREGNANCY, PAEDIATRIC NEPHROLOGY

#### Recent findings in ADPKD

- Utility of prognostic scores in ADPKD  
**Emilie Cornec-Le Gall**, Brest, France
- Low-osmolar diet and adjusted water intake in ADPKD  
**Albert Ong**, Sheffield, United Kingdom
- New genes for cystic kidneys and liver  
**Peter Harris**, Rochester, U.S.A.
- Use of urine peptidome analysis in ADPKD  
*Speaker to be confirmed*

#### Paediatric nephrology

- Long-term outcome of patients with Lowe syndrome and Dent disease 2  
**Detlef Bockenhauer**, London, United Kingdom
- Primary disease recurrence - effects on paediatric renal transplantation outcomes  
*Speaker to be confirmed*
- Methylmalonic aciduria (MMA): new therapeutic perspectives  
*Speaker to be confirmed*
- Minimal Change Disease  
**Marina Vivarelli**, Rome, Italy



#### Pregnancy, CKD and hypertension

- The role of antihypertensive treatment in pregnant women with diabetic nephropathy  
**Elisabeth R. Mathiesen**, Copenhagen, Denmark
- The role of home blood pressure measurements in pregnancy complicated by hypertension  
*Speaker to be confirmed*
- Preconception cardiovascular risk factors for gestational hypertension and preeclampsia  
*Speaker to be confirmed*
- Preeclampsia - does it predict kidney and cardiovascular disease in the future  
*Speaker to be confirmed*
- Complement activation in kidneys of women with preeclampsia  
**Cees Van Kooten**, Leiden, The Netherlands

## Track 3

### GLOMERULAR DISEASES AND GENERAL CLINICAL NEPHROLOGY

#### Membranous nephropathy: the evolving story

- Advances in the pathogenesis of membranous nephropathy  
**Pierre Ronco**, Paris, France
- Membranous nephropathy and cancer  
**Rolf A.K. Stahl**, Hamburg, Germany
- New therapeutic perspectives from recent trials  
**Jack F.M. Wetzels**, Nijmegen, The Netherlands

#### IgA nephropathy: from genes to therapeutic controversies

- From genetics to pathophysiology  
**Jan Novak**, Birmingham, U.S.A.
- Towards pathology-based therapy? Towards a personalized therapy in IgAN  
**Rosanna Coppo**, Turin, Italy
- From experimental models to new treatment options in humans  
**Renato Monteiro**, Paris, France
- New and next therapeutic approaches  
**Jürgen Floege**, Aachen, Germany

#### Plasma cell dyscrasias and the kidney

- Myeloma cast nephropathy - any role for extracorporeal treatments?  
**Frank Bridoux**, Poitiers, France
- Primary amyloidosis - current best practices  
*Speaker to be confirmed*
- Light chain deposition disease  
*Speaker to be confirmed*
- MGUS and glomerulonephritis - how to find a causal relationship and how to treat  
**Sanjeev Sethi**, Rochester, U.S.A.

#### Rituximab in immune mediated glomerular diseases: one drug does not fit all

- Anti-B cell targeted therapy: anti CD20 and other approaches  
*Speaker to be confirmed*
- Rituximab in idiopathic membranous nephropathy  
**Pierre Ronco**, Paris, France
- Rituximab in IgA nephropathy  
**Fernando Fervenza**, Rochester, USA
- Rituximab in ANCA vasculitis  
**David Jayne**, Cambridge, United Kingdom

#### Lupus and vasculitis - recent advances in therapy

- Newer agents in the treatment of SLE nephritis  
**David Jayne**, Cambridge, United Kingdom
- Anti-GBM disease  
**Mårten Segelmark**, Linköping, Sweden



- IgA-vasculitis in adults  
**Alan D. Salama**, London, United Kingdom
- Improving survival in ANCA associated vasculitis  
**Wladimir M. Szpirt**, Copenhagen, Denmark

#### Glomerular diseases in the Omics era

- Large-scale genomic studies: what they have taught us  
*Speaker to be confirmed*
- An integrated view of glomerular pathology  
*Speaker to be confirmed*
- Transcontinental Omics studies  
**Xueqing Yu**, Guangzhou, P.R. China
- Integrative omics approach for comprehensive IgA nephropathy  
**Francesco Paolo Schena**, Bari, Italy

#### Track 4

### CKD - PATHOPHYSIOLOGY, EPIDEMIOLOGY, PREVENTION, PROGRESSION, AGEING

#### Update in plasmapheresis for treating kidney diseases

- Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome  
**Petar Kes**, Zagreb, Croatia
- Renal transplantation  
*Speaker to be confirmed*
- Anti-neutrophil cytoplasm antibodies-associated vasculitis  
**Charles Pusey**, London, United Kingdom
- Focal segmental glomerulosclerosis  
*Speaker to be confirmed*

#### Progression of chronic kidney disease - hot issues beyond blood pressure and renin-angiotensin system

- Does antidiabetic drugs prevent chronic kidney disease progression?  
**Christoph Wanner**, Würzburg, Germany
- Interventional antihypertensive therapies and chronic kidney disease - a new window of opportunity?  
**Johannes F.E. Mann**, Munich, Germany
- Does metabolic acidosis correction prevent chronic kidney disease progression?  
**Marcin Adamczak**, Katowice, Poland
- Hyperuricemia and chronic kidney disease progression  
**Ivan Rychlik**, Prague, Czech Republic

#### New biomarkers of CKD progressions

- Circulating permeability factor (suPAR)  
**Jack F.M. Wetzels**, Nijmegen, The Netherlands
- Phosphate toxicity and CKD progression  
**Markus Ketteler**, Coburg, Germany
- Clinical consequences of hypervolemia in CKD patients  
**Andrzej J. Wiecek**, Katowice, Poland

- Serum Klotho concentration - marker of CKD progression and cardiovascular complications?  
**Makoto Kuro-o**, Shimotsuke, Japan

#### Interstitial fibrosis and mechanisms of CKD progression

- New concepts in the pathogenesis of interstitial fibrosis  
**Peter Boor**, Aachen, Germany
- Are there early biomarkers of interstitial fibrosis?  
**Christos Chatziantoniou**, Paris, France
- HIF as a link between anaemia and renal fibrosis  
*Speaker to be confirmed*
- Interstitial fibrosis in kidney transplant recipients  
**Marian Klinger**, Wroclaw, Poland

#### Controversy: too much Nephrology?

- The CKD epidemics is overstated
- The CKD epidemics is real and concerning

#### Focus on surrogate end-points in Nephrology

- Validation of clinical end-points in Nephrology: less simple than it may seem  
**Kitty J. Jager**, Amsterdam, The Netherlands
- Proteinuria as a clinical end-point in clinical trials in Nephrology: acceptable but not perfect  
*Speaker to be confirmed*
- Coronary calcification as a cardiovascular end-point in clinical trials in nephrology: lights and shades  
**Gérard London**, Fleury-Mérogis, France

#### CKD as a public health priority: organizational models

- CKD Epidemiology in 2017-2050: primary and secondary prevention  
*Speaker to be confirmed*
- How can we effectively deploy Community Nephrology  
**Charles Tomson**, Bristol, United Kingdom
- Cardiovascular-renal clinics  
**Adeera Levin**, Vancouver, Canada

#### n-3 PUFA in CKD: does it matter?

- n-3 PUFA and CKD: epidemiological data and follow-up
- Arrhythmias and sudden cardiac death in HD patients: is n-3 PUFA of relevance?
- n-3 PUFA, inflammation and fibrosis. New insights
- n-3 PUFA and interventional studies relevant for the nephrologist

#### CKD - new therapeutic approaches

- New treatments in diabetic kidney disease  
**Peter Rossing**, Gentofte, Denmark
- Blood pressure regulation in CKD stage 1-5 (non-dialysis). Achievement of treatment goals and adherence to treatment  
*Speaker to be confirmed*



# Preliminary Scientific Programme

- Renal New Nordic Diet  
*Speaker to be confirmed*
- CKD 1-5: focus on calcium, glucose or lipids?  
*Speaker to be confirmed*

## Track 5

### END-STAGE RENAL DISEASE, HAEMODIALYSIS

#### Scheduling dialysis and hemodiafiltration in 2018: a new portfolio?

- Daily and frequent dialysis schedules: rationale, logistics and outcomes  
*Speaker to be confirmed*
- Incremental dialysis  
*Speaker to be confirmed*
- High convective volume in hemodiafiltration: an open question  
**Francesco Locatelli**, Lecco, Italy

#### The non-dialysis pathway in ESRD

- Palliative care in ESRD: an overview  
*Speaker to be confirmed*
- End-of-life perspectives in haemodialysis  
**Stefan H. Jacobson**, Stockholm, Sweden
- The non-dialysis pathway: models of care  
**Elizabeth Krarup**, Herlev, Denmark
- Patient-reported outcome measures in ESRD: relevance for renal palliative care  
*Speaker to be confirmed*



#### Uremic toxicity - New insights

- Uremic toxins and the gut  
**Griet Glorieux**, Ghent, Belgium
- Uremic toxins and cardiovascular outcomes  
**Ziad Massy**, Paris, France
- Uremic toxins and bone  
**Tilman Druke**, Villejuif, France
- Uremic toxins and inflammation  
**Peter Stenvinkel**, Stockholm, Sweden

#### New methods of anaemia management in CKD patients

- PHIs - safety and efficacy - results from recent clinical trials  
*Speaker to be confirmed*
- Iron supplementation in CKD patients - what is the optimal dose and optimal route of administration in 2018  
**Iain C. Macdougall**, London, United Kingdom
- Mechanisms of hypertension induced by erythropoietin and related agents  
*Speaker to be confirmed*
- What is the future of rHuEPO?  
**Francesco Locatelli**, Lecco, Italy

#### Neurologic disturbances in CKD

- Cognitive disturbances  
**David Goldsmith**, London, United Kingdom
- Sleep disturbances  
*Speaker to be confirmed*
- Headaches during haemodialysis - headaches and treatment  
*Speaker to be confirmed*

#### Cardiovascular calcifications in CKD

- Pathophysiology of vascular calcification  
**Mario Cozzolino**, Milan, Italy
- Vitamin K  
**Jürgen Floege**, Aachen, Germany
- Calcium sensing receptors  
**Jordi Bover**, Barcelona, Spain
- Energy-dense diets and vascular calcification  
**J. Mariano Rodriguez Portillo**, Cordoba, Spain

#### Treatment of CKD-MBD

- Which phosphate binder in CKD patients?  
*Speaker to be confirmed*
- Calcimimetics or vitamin D derivatives in ESRD patients?  
**John Cunningham**, London, United Kingdom
- Osteoporosis in patients with CKD  
*Speaker to be confirmed*
- Treatment and prevention of fractures in kidney graft recipients  
**Rudolf Wüthrich**, Zurich, Switzerland

#### The diagnosis of Heart Failure in End Stage Kidney Disease (ESKD): a lingering dilemma

- Diagnosis, classification and staging in Medicine: methodology issues
- The new Heart Failure Classification for ESKD patients
- The new Heart Failure Classification in the real world

#### DOPPS - The sweet truth: Optimizing care in advanced CKD and dialysis with a focus on diabetic patients



- DOPPS Program: The burden of diabetes in advanced CKD and dialysis  
*Speaker to be confirmed*
- PDOPPS: Variation in the PD prescription, glucose exposure and outcomes  
**Mark Lambie**, Stoke-On-Trent, United Kingdom
- DOPPS: Hepatitis C in HD patients - prevalence trends over 20 years, outcomes and use of newer treatments  
**Michel Jadoul**, Brussels, Belgium
- CKDopps: Diabetes treatment, control and hypoglycemia in patients with advanced CKD  
**Bénédicte Stengel**, Villejuif, France
- EURODOPPS: Outcomes according to different strategies of HbA1c use among diabetic HD patients  
**Ionut Nistor**, Iasi, Romania

## Track 6 HOME THERAPIES, PERITONEAL DIALYSIS

### Lessons from International Databases

*In collaboration with*

#### the International Society for Peritoneal Dialysis (ISPD)



- SONG-PD  
*Speaker to be confirmed*
- Achieving optimal catheter function. PDOPPS and UK-Catheter Study  
**Martin Wilkie**, Sheffield, United Kingdom
- Update from the IPPN (International Paediatric PD Network)  
*Speaker to be confirmed*

### Optimising clinical outcomes and technique survival

- How to reduce technique failure due to peritonitis - the ANZDATA experience  
*Speaker to be confirmed*
- The role of training in peritonitis prevention - what we have learned from the PEPS Study (Prevention of Peritonitis in Peritoneal Dialysis)  
**Susanne Ljungman**, Gothenburg, Sweden
- What is the role of assisted PD in the outcomes of frail elderly patients?  
**Edwina Brown**, London, United Kingdom

### Optimising fluid management in PD patients

- Bioimpedance: what have we learned from the IPOD-PD Study
- Managing blood pressure in PD patients: what is the optimal balance between bioimpedance directed volume status, salt restriction, pharmacological management and sodium removal?
- What is the role of low sodium solutions?

### Home haemodialysis in Europe 2018

- What to do for more frequent use of home haemodialysis in Europe  
*Speaker to be confirmed*
- Home haemodialysis and control of phosphatemia  
*Speaker to be confirmed*
- Home haemodialysis and quality of life  
**Edwina Brown**, London, United Kingdom

## Track 7 TRANSPLANTATION AND IMMUNOLOGY

### Hot and new in transplantation: selected topics from 2017/18

- Relevant outcomes? The SONG Initiative (Standardized Outcomes In Nephrology)  
**Lionel Rostaing**, Grenoble, France
- Steroid withdrawal: if and when?  
**Maria Haller**, Linz, Austria
- Calcineurin inhibitor withdrawal: if and when?  
**Daniel Abramowicz**, Antwerp, Belgium
- Dialysis vintage and outcomes  
**Rainer Oberbauer**, Vienna, Austria

### Humoral immunity (HLA and nonHLA)

- Allorecognition revisited  
**Frans H.J. Claas**, Leiden, The Netherlands
- Histopathology of humoral alloimmunity  
*Speaker to be confirmed*
- Anti-HLA antibodies - consequences and intervention  
*Speaker to be confirmed*
- Sensitization to non-HLA epitopes - is this clinical relevant?  
*Speaker to be confirmed*

### Expanding the donor pool (deceased and live donors) KPD, ABOi, machine perfusion

- How to set up a KPD Program  
**Ondrej Viklicky**, Prague, Czech Republic
- ABO-I and HLA-I transplantation  
**Umberto Maggiore**, Parma, Italy
- DCD - Programs  
*Speaker to be confirmed*
- ESP - Programs and elderly living donors  
**Johan W. De Fijter**, Leiden, The Netherlands

### Post transplantation diabetes mellitus - relation to obesity and new options/challenges

- LOGO DNS
- Peripheral or central resistance-pre and post transplant factors in PTDM  
**Morten Buus Jørgensen**, Copenhagen, Denmark
- Insulin secretion and immunosuppression related pathogenesis of PTDM  
*Speaker to be confirmed*
- New gastrointestinal targets for glucose control in obesity and type 2 diabetes - any role in diabetes after transplantation?  
*Speaker to be confirmed*
- Clinical evaluation of PTDM  
**Esteban Porrini**, La Laguna, Spain

# Preliminary Scientific Programme

## Risk profiling in renal transplant patients

- Metabolic risk profile in renal transplant candidates and in renal transplant patients  
**Umberto Maggiore**, Parma, Italy
- Non-invasive cardiac imaging in renal transplant candidates and in renal transplant patients  
*Speaker to be confirmed*
- Nocturnal hypertension and renal function loss in renal transplant patients  
*Speaker to be confirmed*

## Track 8

### HYPERTENSION, DIABETES, VASCULAR DISEASES

#### Hot topics in hypertension

- Early vascular aging, hypertension and cardiovascular disease  
**Stéphane Laurent**, Paris, France
- Looking for optimal target blood pressure: implications of the recent trials  
**Sverre E. Kjeldsen**, Oslo, Norway
- Measuring, analyzing and managing drug adherence  
**Michel Burnier**, Lausanne, Switzerland
- Potential new targets for antihypertensive therapy  
**Krzysztof Narkiewicz**, Gdansk, Poland

#### A new life for sodium in Nephrology

- Sodium and ADPKD progression  
**Vicente Torres**, Rochester, U.S.A.
- Sodium and the evolution of CKD  
**Gerjan Navis**, Groningen, The Netherlands
- Inflammatory mechanisms by sodium in hypertension and CKD  
*Speaker to be confirmed*

#### Diabetic nephropathy

- Urine proteome - is there a role in predicting and monitoring diabetic nephropathy  
**Peter Rossing**, Gentofte, Denmark
- SGLT2 inhibitors, mechanisms behind cardiovascular and renal protection?  
**Bo Feldt-Rasmussen**, Copenhagen, Denmark
- Incretin based therapies, mechanisms behind cardiovascular and renal protection?  
*Speaker to be confirmed*
- Ongoing studies in the field  
*Speaker to be confirmed*



## Track 9

### ACUTE KIDNEY INJURY AND INTENSIVE CARE NEPHROLOGY

#### AKI biomarkers and risk factors

- Micro RNA  
**Danilo Fliser**, Homburg/Saar, Germany
- Leukocyte integrin CD11b/CD18  
*Speaker to be confirmed*
- Histones and Neutrophil  
**Hans-Joachim Anders**, Munich, Germany
- Biomarkers for early detection and prognosis of AKI  
**Raymond Vanholder**, Ghent, Belgium

#### AKI in various circumstances

- AKI in surgery patients  
*Speaker to be confirmed*
- AKI after kidney transplantation  
**Alexandre Hertig**, Paris, France
- AKI during disasters  
**Mehmet Sukru Sever**, Istanbul, Turkey
- Consulting the patient with AKI in other clinics: what should be stressed by the nephrologist?  
**Mustafa Arici**, Ankara, Turkey

#### Renal Replacement Therapy in the Intensive Care Unit

- Epidemiology of Acute Kidney Injury in critically ill children and young adults  
*Speaker to be confirmed*
- Continuous Renal Replacement Therapy  
**Esteban Poch**, Barcelona, Spain
- Pro RRT Delayed strategy  
**Julien Maizel**, Amiens, France
- Con RRT Delayed strategy  
*Speaker to be confirmed*

## SPECIAL SESSION

### Nephrology Pearls

## CME COURSES

### IWG - Immunonephrology Working Group



Part 1

#### **Cyclophosphamide in glomerular disease: is this old drug still to be used or does it have to be dismissed?**

- Introduction and the case of ANCA-associated vasculitis  
*Speaker to be confirmed*
- The case of lupus nephritis  
**Vladimir Tesar**, Prague, Czech Republic
- The case of membranous nephropathy  
**Jack F.M. Wetzels**, Nijmegen, The Netherlands
- The case of minimal change and focal segmental glomerulosclerosis  
**Claudio Ponticelli**, Milan, Italy

Part 2

#### **Renal involvement in rare inflammatory diseases**

- IgG4-related renal disease  
*Speaker to be confirmed*
- Inflammation in crystal nephropathies  
**Hans-Joachim Anders**, Munich, Germany
- Renal involvement in Familial Mediterranean Fever and Systemic Autoinflammatory Diseases  
*Speaker to be confirmed*
- Renal involvement in scleroderma  
*Speaker to be confirmed*

### (EURECA-m Working Group - European RENal and CARDiovascular Medicine)



#### **The challenge of decreasing cardiovascular mortality in CKD**

Part 1

#### **New therapeutic approaches to improve cardiovascular outcomes in CKD patients**

- Challenges and opportunities of potassium management in CKD and hypertension  
**Patrick Rossignol**, Vandoeuvre-Les-Nancy, France
- Cardio- and nephroprotective properties of SGLT-2 inhibitors: mechanisms and future potential  
**Pantelis A. Sarafidis**, Thessaloniki, Greece
- Iron supplementation in kidney and heart crosstalk: a hope for heart failure treatment  
**Mehmet Kanbay**, Istanbul, Turkey

Part 2

#### **Focus on prevention: health economy, blood pressure targets and choice of anticoagulation**

- The health-economy of CKD: a plea for more prevention  
**Raymond Vanholder**, Ghent, Belgium
- Hypertension metrics and treatment targets in renal transplantation: an update  
*Speaker to be confirmed*
- Anticoagulation in CKD patients with atrial fibrillation  
*Speaker to be confirmed*

### DESCARTES Working Group (Developing Education Science and Care for Renal Transplantation in European States) in collaboration with EKITA, the Organ Expert Section of ESOT on kidney transplantation in Europe



#### **Kidney transplantation: what are the challenges and opportunities ahead?**

- The European paired exchange program  
**Rainer Oberbauer**, Vienna, Austria
- Machine perfusion: does it help to improve outcomes?  
**Gabriel C. Oniscu**, Edinburgh, United Kingdom
- Minimisation strategies in kidney transplantation: are we making progresses?  
**Ondrej Viklicky**, Prague, Czech Republic
- FSGS in children  
**Licia Peruzzi**, Turin, Italy
- The upcoming immunosuppressive drugs  
*Speaker to be confirmed*
- Donor specific antibodies before and after transplantation  
*Speaker to be confirmed*
- The future of kidney allocation within Eurotransplant  
**Uwe Heemann**, Munich, Germany

### EUDIAL Working Group - European Dialysis



Part 1

#### **Targets of treatment in dialysis patients**

- Does achievement of solute clearance targets improve patient outcomes
- Does achievement of blood pressure targets improve patient outcomes
- Patient perspective of dialysis - what really matters - what targets do patients want

Part 2

#### **How to reduce cardiovascular risk?**

- Detection, prevention and management of cardiac arrhythmias during dialysis
- Atrial fibrillation: rate or rhythm control, anticoagulation: yes or no
- Does bioimpedance and lung ultrasound guided assessment of target weight improve outcomes



# Preliminary Scientific Programme

## ERA-EDTA Registry



## European Renal Best Practice



## DIABESITY - Working Group researching on the nephrological impact in relation to diabetes and obesity Insulin resistance and renal disease



- Insulin resistance: pathogenesis and definitions  
*Speaker to be confirmed*
- Muscle or liver?  
**Morten Buus Jørgensen**, Copenhagen, Denmark
- Insulin resistance: cause or consequence of renal disease?  
*Speaker to be confirmed*
- CKD, dialysis and insulin resistance  
**Danilo Fliser**, Homburg/Saar, Germany
- Uremia, insulin resistance and beta-cell damage  
**Laetitia Koppe**, Lyon, France
- Prediabetes and insulin resistance in the waiting list for renal transplantation  
**Armando Torres**, La Laguna (Tenerife), Spain

## Fluid and electrolyte disorders

## EUTox Working Group - European Uremic Toxin



## Uremic toxins: sources and alterations leading to the uremic state

- Systems medicine, molecular mechanisms and pathways involved in CKD  
**Harald Mischak**, Hannover, Germany
- Molecular modifications of proteins and peptides in CKD  
**Joachim Jankowski**, Aachen, Germany
- MicroRNA and CKD  
**Laurent Metzinger**, Amiens, France
- Sulfur amino acid metabolism derangement in uremia  
**Alessandra Perna**, Naples, Italy
- Understanding the gut-kidney axis in chronic kidney disease  
**Rosalinde Masereeuw**, Utrecht, The Netherlands
- Uremic toxins and the gut microbiota  
**Griet Glorieux**, Ghent, Belgium

## EuroPD



- How do we best help patients make an informed modality choice?
- What is the best way to deliver assisted peritoneal dialysis?
- How can we best deliver an integrated home therapies dialysis programme?
- Preventing technique failure in PD - what does it mean for the small dialysis programme?

## Vascular Access Society (VAS)

## CKB-MBD Working Group Emerging insights in CKD-MBD



- Position of gastrointestinal sodium-phosphate transporter inhibition  
**Ziad Massy**, Paris, France
- Novel approaches to treat renal osteodystrophy  
*Speaker to be confirmed*
- CKD-MBD phenotypes and all-cause mortality  
**Marc Vervloet**, Amsterdam, The Netherlands
- Novel compounds to regress ectopic calcification  
**Mario Cozzolino**, Milan, Italy
- Ten years research on FGF23: will it ever enter clinical practice?  
*Speaker to be confirmed*
- Treatment of CKD-MBD after renal transplantation  
**Pieter Evenepoel**, Leuven, Belgium

## WGIKD - Working Group on Inherited Kidney Diseases



## What's new in rare kidney diseases?

- Ascertaining pathogenicity of genetic variants in congenital and inherited kidney disorders  
*Speaker to be confirmed*
- Claudinopathies: a new class of tubulopathies  
*Speaker to be confirmed*
- Diagnostic and therapeutic management of hypophosphatemic rickets from infancy to adulthood  
**Dominique Prié**, Paris, France
- Novel therapeutic approaches in primary hyperoxaluria  
*Speaker to be confirmed*
- What's new in Tuberous Sclerosis Complex?  
**Roser Torra**, Barcelona, Spain
- Insights from urinary exosome analysis in inherited kidney diseases  
**Kirsten Y. Renkema**, Utrecht, The Netherlands
- Transitioning rare kidney disease patients from paediatric to adult care  
*Speaker to be confirmed*

## Rheumatology for nephrologists

## Oncology for nephrologists

**ERN Working Group -  
European Renal Nutrition**



**Presentation of the 2018 KDOQI Clinical Practice  
Guideline for Nutrition in CKD**

- Introduction, overview and rationale for the guidelines  
**T. Alp Ikizler**, Nashville, U.S.A.
- Methodology and development of the clinical evidence library  
*Speaker to be confirmed*
- Guideline recommendations for macronutrients  
**Denis Fouque**, Lyon, France
- Guideline recommendations for micronutrients  
**Daniel Teta**, Sion, Switzerland
- Guideline recommendations for electrolytes and other nutrients  
*Speaker to be confirmed*

**EULIS, the Section  
of Urolithiasis of the  
European Association of Urology**



**Ethics**